HUP2200222A1 - MCHR1 antagonisták a Prader-Willi szindróma kezelésére - Google Patents

MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Info

Publication number
HUP2200222A1
HUP2200222A1 HU2200222A HUP2200222A HUP2200222A1 HU P2200222 A1 HUP2200222 A1 HU P2200222A1 HU 2200222 A HU2200222 A HU 2200222A HU P2200222 A HUP2200222 A HU P2200222A HU P2200222 A1 HUP2200222 A1 HU P2200222A1
Authority
HU
Hungary
Prior art keywords
prader
treatment
willi syndrome
mchr1 antagonists
mchr1
Prior art date
Application number
HU2200222A
Other languages
English (en)
Inventor
Olah Mark Dr
Boros Andras Dr
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HU2200222A priority Critical patent/HUP2200222A1/hu
Priority to PCT/IB2023/056245 priority patent/WO2023242810A1/en
Publication of HUP2200222A1 publication Critical patent/HUP2200222A1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
HU2200222A 2022-06-17 2022-06-17 MCHR1 antagonisták a Prader-Willi szindróma kezelésére HUP2200222A1 (hu)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU2200222A HUP2200222A1 (hu) 2022-06-17 2022-06-17 MCHR1 antagonisták a Prader-Willi szindróma kezelésére
PCT/IB2023/056245 WO2023242810A1 (en) 2022-06-17 2023-06-16 Mchr1 antagonists for the treatment of prader-willi syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU2200222A HUP2200222A1 (hu) 2022-06-17 2022-06-17 MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Publications (1)

Publication Number Publication Date
HUP2200222A1 true HUP2200222A1 (hu) 2023-12-28

Family

ID=89993598

Family Applications (1)

Application Number Title Priority Date Filing Date
HU2200222A HUP2200222A1 (hu) 2022-06-17 2022-06-17 MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Country Status (2)

Country Link
HU (1) HUP2200222A1 (hu)
WO (1) WO2023242810A1 (hu)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534703A2 (en) * 2002-06-12 2005-06-01 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
AU2003285160B2 (en) 2002-11-06 2009-06-04 Amgen Inc. Fused heterocyclic compounds
JP2007509158A (ja) 2003-10-23 2007-04-12 グラクソ　グループ　リミテッド 肥満、糖尿病、うつ病及び不安を治療するためのｍｃｈｒ１アンタゴニストとしての３−（４−アミノフェニル）チエノピリミド−４−オン誘導体
TW200609219A (en) 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
EP2240481A1 (en) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
JP2012528870A (ja) 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン
JPWO2011058943A1 (ja) * 2009-11-11 2013-03-28 塩野義製薬株式会社 Ｍｃｈｒ１アンタゴニスト活性を有する化合物とｎｐｙｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
WO2011127643A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
AR096848A1 (es) 2013-07-09 2016-02-03 Takeda Pharmaceuticals Co Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
CN115350184A (zh) * 2020-01-10 2022-11-18 康圣博施医药有限公司 药物的治疗组合以及其使用方法

Also Published As

Publication number Publication date
WO2023242810A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
IL284363A (en) RNA editing oligonucleotides for the treatment of Asher syndrome
GB202106881D0 (en) Therapeutic solid dosage forms
IL276501A (en) CGAS inhibitors containing 2,3,4,5-tetrahydro-1H-pyrado[B-4,3]indoles for the treatment of autoinflammatory diseases
IL288061A (en) Compounds and methods for treating covid-19
IL285999A (en) jak1 inhibitor pathway for the treatment of impaired chronic lung allograft function
IL292657A (en) Therapeutic history of interleukin-22
EP4081201A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MANY INFLAMMATORY DISORDERS
IL292690A (en) mrgprx2 antagonists for the treatment of inflammatory disorders
ZA202109826B (en) Nk1 inhibitors for the treatment of malaria
HUP2200222A1 (hu) MCHR1 antagonisták a Prader-Willi szindróma kezelésére
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
EP4121403A4 (en) NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS
ZA202210315B (en) Peptide for the treatment of cytokine storm syndrome
SG11202110644WA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL290540A (en) Compounds suitable for the treatment and prevention of muscle wasting and other conditions
EP4096653A4 (en) COMPOSITIONS FOR TREATING ANGIOLIPOMA
GB202217355D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
EP4087569A4 (en) METHODS OF ADMINISTRATION OF NALBUPHINE
IL280312A (en) Process for preparing bromodomain inhibitors
SG10201902000YA (en) Isthmin 1 for treatment of lung inflammation
GB202011523D0 (en) Neuromodulation for the treatment of critical illness
SG11202110678UA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ZA202105477B (en) Selected artemisinin dimers for the treatment of leishmaniasis
GB2592200B (en) Sanitary ware apparatus
GB202301974D0 (en) The capability of becoming telepathic